@article{67e414f5611548479907a004ee132b86,
title = "Expanding indications of existing drugs and associated costs under risk reimbursement models.",
author = "Page, \{Ray D.\} and Ellis, \{Peter G.\} and Kathleen Lokay and Amanda Barry",
note = "e18306 Background: New payment models in oncology will likely include taking risk on drug costs. While new drugs could be excluded, existing drugs with expanded indications are problematic as the payer has limited data needed to exclude these costs. Recent label expansion for pembrolizumab (PB) in 1st line NSCLC for > 50\% PD-L1 expression is an example of this risk.",
year = "2017",
month = may,
day = "30",
doi = "10.1200/JCO.2017.35.15\_SUPPL.E18306",
language = "American English",
volume = "35",
journal = "Journal of Clinical Oncology",
}